Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | CTSD | P07339 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3362006 | 0.83 | ALDH1A1 (0.62) | HPGDTP53GLACTSDKMT2A | |
| SCHEMBL6424788 | 0.80 | HPGD (0.46) | HPGDKMT2AMEN1ALDH1A1POLB | |
| SCHEMBL5656202 | 0.79 | HPGD (0.61) | HPGDTP53GLACTSDALDH1A1 | |
| SCHEMBL3038950 | 0.78 | KMT2A (0.74) | HPGDTP53GLACTSDKMT2A | |
| SCHEMBL11761482 | 0.78 | NAMPT (0.71) | HPGDTP53GLACTSDALDH1A1 | |
| SCHEMBL6360123 | 0.78 | HPGD (0.65) | HPGDTP53GLACTSDKMT2A | |
| SCHEMBL30848493 | 0.77 | HPGD (0.63) | HPGDTP53GLACTSDKMT2A | |
| SCHEMBL3365176 | 0.77 | CTSD (0.68) | HPGDTP53GLACTSDKMT2A | |
| SCHEMBL10243095 | 0.77 | STAT3 (0.64) | HPGDTP53GLACTSDKMT2A | |
| SCHEMBL7956519 | 0.77 | HPGD (0.63) | HPGDTP53GLACTSDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399416-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-11-02 | — | — | EP | claimed |
| EP-1399416-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-12-28 | — | — | EP | claimed |
| US-6852882-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-08 | — | — | US | claimed |
| US-20040157916-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2004-08-12 | — | — | US | claimed |
| EP-1399416-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2004-03-24 | — | — | EP | claimed |
| WO-2002098901-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-12-12 | — | — | WO | claimed |
| EP-1399416-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-1399416-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6852882-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040157916-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2004-08-12 | — | — | US | disclosed |
| EP-1399416-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002098901-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157916-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | HPGD 2537/4885TP53 4245/4885GLA 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.